Matrix Laboratories Limited, a subsidiary of Mylan Inc. (NASDAQ: MYL), is one of the world’s largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs.

Based in Hyderabad, India, Matrix also maintains an impressive portfolio of finished dosage forms of generic antiretroviral (ARV) products, which treat people living with HIV/AIDS, including pediatric therapies. The hallmark of Mylan and Matrix’s ARV franchise to date is affordability, as it has continually and significantly reduced drug costs. As a result, the company’s ARV products are helping nearly one-third of all people receiving treatment today for HIV/AIDS in the developing world.

During 2009, Mylan received the World Health Organization’s approval of the heat-stable ARV tablet, Lopinavir/Ritonavir, which the company formulated before any other company – brand or generic. Mylan and Matrix intend to build on this achievement by introducing innovations that expand people’s access to ARV medications and related resources.

The development and manufacture of high quality intermediates and APIs are critical to Mylan’s continued success in delivering innovative and affordable products for domestic and international markets. Matrix will achieve this through its dedication to Innovation, Integrity, Reliability, Service and Teamwork.

At Mylan, we work around the clock and around the globe to help provide 7 billion people access to medicine. We aim to produce high quality, more affordable pharmaceuticals affordable pharmaceuticals to be made available everywhere, every day – no exceptions. Our global network of employees is obsessed with quality and dedicated to Innovation, Integrity, Reliability, Service and Teamwork.

View our ARV Brochure (June 2010) by clicking here.